It is noteworthy that although 57% of the tumours with PDGFRA mutations in our series were classified as intermediate or high risk according to the NIH consensus (Fletcher et al, 2002), most of these tumours were classified as low or very low risk according to the AFIP risk classification (Miettinen and Lasota, 2006). The gene discussed is PDGFRA; the disease is neoplasm.